Presentation of results for second quarter and first half of 2012

22 Aug, 2012 09:44 CET

Presentation of results for second quarter and first half of 2012 will
take place 09:00 (Norwegian time), Wednesday 29 August at Felix
Conference Centre, Bryggetorget 3, Aker brygge in Oslo.

The presentation will be available on webcast with the following link:

http://media01.smartcom.no/Microsite/start.aspx?eventid=6607

After the presentation the webcast will be available on demand on the
webpage www.diagenic.com under 'Investor relations'.
Contact:

Henrik Lund, CEO

Telephone: 47 90971219

e-mail:  
About DiaGenic ASA

DiaGenic seeks to create value for patients, partners, and investors by
developing innovative and more patient friendly methods for early
detection of diseases utilizing DiaGenic's unique concept. The concept
implies that a disease evokes systemic responses in the blood unique for
the disease, and which can be measured by using blood samples.

DiaGenic is a world leader in identifying these gene expression
signatures in peripheral blood and is focused on the development of
biomarkers in the field of Alzheimer's disease and Parkinson's disease.
DiaGenic's Alzheimer's disease development program includes the CE
marked diagnostic test ADtect®, for detection of mild to moderate
Alzheimer's disease, and MCItect®which is under development for
identifying patients with very early stages of Alzheimer's disease
(prodromal AD).

DiaGenic's concept is protected through an extensive patent portfolio.
DiaGenic promotes its products and services towards leading
pharmaceutical, imaging and diagnostic companies. DiaGenic is located in
Norway and listed on the Oslo Stock Exchange. For more information
please visit: www.diagenic.